Innate Pharma (IPHA) Stock Forecast & Price Target

$2.13

+0.04 (+1.91%)

(As of 07/26/2024 ET)

Innate Pharma - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy
Based on 1 Analyst Ratings

Based on 1 Wall Street analysts who have issued ratings for Innate Pharma in the last 12 months, the stock has a consensus rating of "Buy." Out of the 1 analysts, 1 has given a buy rating for IPHA.

Consensus Price Target

$9.75
357.75% Upside

High Forecast	$11.50
Average Forecast	$9.75
Low Forecast	$8.00

According to the 1 analysts' twelve-month price targets for Innate Pharma, the average price target is $9.75. The highest price target for IPHA is $11.50, while the lowest price target for IPHA is $8.00. The average price target represents a forecasted upside of 357.75% from the current price of $2.13.

Type	Current Forecast 7/28/23 to 7/27/24	1 Month Ago 6/28/23 to 6/27/24	3 Months Ago 4/29/23 to 4/28/24	1 Year Ago 7/28/22 to 7/28/23
Consensus Rating	Buy	Buy	Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	1 Buy rating(s)	1 Buy rating(s)	1 Buy rating(s)	3 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$9.75	$9.75	$9.75	$10.63
Forecasted Upside	357.75% Upside	262.90% Upside	265.17% Upside	298.31% Upside

Get Innate Pharma Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for IPHA and its competitors with MarketBeat's FREE daily newsletter.

Ad The Oxford Club

Alex's "Next Magnificent Seven" Stocks

Today Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time to watch it.

Watch Alex's "Next Magnificent Seven" presentation now.

IPHA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

IPHA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Innate Pharma Stock vs. The Competition

Type	Innate Pharma	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.72	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	357.75% Upside	3,123.18% Upside	9.15% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
6/12/2024	HC Wainwright 3 of 5 stars		Reiterated Rating	Buy ➝ Buy	$11.50 ➝ $11.50	+351.87%
9/18/2023	Citigroup 3 of 5 stars		Lower Target		$12.00 ➝ $8.00	+169.36%
4/10/2023	SVB Securities 5 of 5 stars		Boost Target		$9.00 ➝ $10.00	+211.53%
11/15/2022	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$10.00 ➝ $9.00	+262.90%
8/3/2022	Kepler Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Arsene Guekam Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	€3.10

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 06:18 AM ET.

IPHA Forecast - Frequently Asked Questions

What is Innate Pharma's forecast for 2024?: According to the research reports of 1 Wall Street equities research analysts, the average twelve-month stock price forecast for Innate Pharma is $9.75, with a high forecast of $11.50 and a low forecast of $8.00.
Should I buy or sell Innate Pharma stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innate Pharma in the last twelve months. There is currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" IPHA shares.
Does Innate Pharma's stock price have much upside?: According to analysts, Innate Pharma's stock has a predicted upside of 262.90% based on their 12-month stock forecasts.
What analysts cover Innate Pharma?: Innate Pharma has been rated by research analysts at HC Wainwright in the past 90 days.
Do Wall Street analysts like Innate Pharma more than its competitors?: Analysts like Innate Pharma more than other "medical" companies. The consensus rating for Innate Pharma is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how IPHA compares to other companies.